Ocular hypertension

ITRI Excels with Eight 2023 R&D 100 Awards, Showcasing Biotechnological Triumph

Retrieved on: 
星期三, 十月 18, 2023
Molecule, Biomedical Research, Electronics, Oak Ridge National Laboratory, Coordination, Intraocular pressure, Ocular hypertension, RFA, Complex, AMD, Pancreas, IOP, Drainage, Injection, Liver, Vance DeGeneres, Infection, CSC, Research, Inflammation, Bleeding, Quality of life, Clinician Administered PTSD Scale, Compal Electronics, Risk, Surgeon, United States Commission on International Religious Freedom, Irritation, ICT, Anxiety, Patient, Macular edema, Breast, ITRI, Pharmaceutical industry, Glaucoma

ITRI's accolades include five net-zero solutions and three novel biomedical technologies, marking a historic win for the institute's biotechnology sector.

Key Points: 
  • ITRI's accolades include five net-zero solutions and three novel biomedical technologies, marking a historic win for the institute's biotechnology sector.
  • "It marks the fifth consecutive year that ITRI's biomedical innovations have earned the prestigious R&D 100 Awards, showcasing the international caliber of Taiwan's biomedical research capabilities," noted ITRI President Edwin Liu.
  • All three award-winning technologies have been transferred to Taiwanese companies, reflecting the Institute's commitment to translating research into practical industrial applications.
  • Beyond its current applications, iRFA's can potentially be extended to breast and orthopedic tumor ablation and even robotic-assisted surgery.

PADAGIS ANNOUNCES THE LAUNCH OF BRINZOLAMIDE OPHTHALMIC SUSPENSION WITH CGT EXCLUSIVITY

Retrieved on: 
星期五, 十月 13, 2023
IOP, Glaucoma, IQVIA, Patient, Ocular hypertension, CGT, Pharmaceutical industry, Mobile phone

Azopt® Ophthalmic Suspension is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma, as monotherapy in patients unresponsive to betablockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to betablockers.

Key Points: 
  • Azopt® Ophthalmic Suspension is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma, as monotherapy in patients unresponsive to betablockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to betablockers.
  • Annual market sales for Azopt® were approximately $74 million in the 12 months ended August 2023 as measured by IQVIA.
  • Padagis President, Pamela Hoffman, stated, "This launch and its accompanying CGT exclusivity demonstrates the ability of the Padagis team to bring complex generic products to the markets that need them.
  • The Padagis team continues to leverage our unique and specialized technical and commercial capabilities to deliver important products to our customers and patients."

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
星期三, 十月 4, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Contact, Ernest, Cerebral edema, Palace, Employment, Pain, Telecanthus, Incidence, Hilton New Orleans Riverside, Steroid, Viral, Macular edema, Herpes simplex, NYSE, Chickenpox, Magazine Street, Canal Street, Conjunctiva, EYE, Tchoupitoulas Street, Risk, Pigment, Intraocular pressure, SM, Optic nerve, FDA, INA War Museum, Iris, Andhra Pradesh Decentralisation and Inclusive Development of All Regions Act, 2020, Fungal infection, Poydras Street, Sclera, Eye, Bausch, History, Slit lamp, Glaucoma, Ocular hypertension, DED, Cornea, IOP, Contact lens, Infection, American Academy, Inflammation, Johnson & Johnson Vision, Vaccinia, Bausch & Lomb, Lens (vertebrate anatomy), Visual acuity, Pharmaceutical industry, Medical device, Hospital, Telescopic sight, Hotel, Gasoline, Nursing, Dietary supplement, Vaccine, Blinking, O.D, Patient

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.

Retrieved on: 
星期二, 九月 26, 2023
Insurance, Latanoprost, IOP, Glaucoma, McKesson Corporation, Research, Pharmacy, NDC, Ocular hypertension, Patient, Mercury (element), ABC, PGA, ANDA, OHT, Pharmaceutical industry, Hospital, Nursing, Thea

WALTHAM, Mass., Sept. 26, 2023 /PRNewswire/ -- Thea Pharma Inc. ("Thea"), the U.S. subsidiary of Europe's leading independent ophthalmic-focused pharmaceutical company, Théa, dedicated to the research, development, and commercialization of ophthalmic products, today announced the launch and availability of IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S. market. Preservative-free latanoprost, launched over ten years ago, is available in 46 countries, mostly under the brand name MONOPROST®, with about 1.5 million patients treated monthly.1 IYUZEH is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) in the U.S. In randomized, controlled clinical trials of patients with POAG or OHT with mean baseline intraocular pressure (IOP) of 19-24 mmHg, IYUZEH lowered IOP by 3–8 mmHg compared to 4–8 mmHg by XALATAN®.2-4  

Key Points: 
  • "Glaucoma is a chronic eye disease that affects the everyday lives of more than 60 million people globally.
  • With IYUZEH now available, eye care providers can effectively treat their POAG and OHT patients with preservative-free latanoprost.
  • "With the launch of IYUZEH in the U.S., Thea is responding to an important unmet need in the treatment landscape.
  • The Thea Savings Card is available to those commercially insured and not enrolled in a state or federally funded program.

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
星期一, 八月 7, 2023
OAG, ASC, Clinical trial, Marketing, AMD, Trial of the century, Line of credit, Eye, SOFR, Month, Inflammation, Șaeș, Pain, Intraocular pressure, Interest, Ocular hypertension, Patient, Allergic conjunctivitis, Ophthalmology, Barings LLC, Growth, Webcast, OHT, Depreciation, Abdominal ultrasonography, Research, Axitinib, FDA, Summit, Treatment, Safety, Beauty salon, Pharmaceutical industry, Telescopic sight, Video game, Birth control, Arms industry

“The progress at Ocular Therapeutix over this last quarter has been significant,” said Antony Mattessich, President and CEO.

Key Points: 
  • “The progress at Ocular Therapeutix over this last quarter has been significant,” said Antony Mattessich, President and CEO.
  • The Company intends to initiate the first of two planned pivotal trials in wet AMD in Q3 2023.
  • Non-cash charges for stock-based compensation and depreciation and amortization were $5.1 million in the second quarter of 2023 versus $4.8 million for the comparable quarter in 2022.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Latest Updates of 7 Viva's Portfolio Companies

Retrieved on: 
星期五, 七月 28, 2023
Dai, FALCON, Head, Acquisition, Patient, Fabry disease, SUA, Tissue, Pharma, Gout, Therapy, Heart failure, CSO, GABAA receptor negative allosteric modulator, Research, NAM, VBI, Small RNA, Medicine, Liver, Growth, CIO, Listeria monocytogenes non-coding RNA, Phase, FDA, URAT1, G protein-coupled receptor, SRT, PAR2, DSM-IV codes, Gq alpha subunit, Glaucoma, Ocular hypertension, SAN, Mercury (element), Allosteric regulation, IOP, Flare, Central nervous system, Drug development, Quality of life, Facet joint arthrosis, RNA, Novartis, Cardiology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Fine chemical, Riparian zone, Domain, Pfizer

WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Key Points: 
  • WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
  • Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
  • In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics.
  • DTx Pharma utilizes its groundbreaking FALCON™ platform, a conjugated oligonucleotide technology using fatty acid ligands, to tackle the delivery challenges of oligonucleotide therapies.

Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Retrieved on: 
星期三, 七月 26, 2023
Biotechnology, FDA, Pharmaceutical, Health, HFA, Respiratory disease, Growth, Ocular hypertension, Propofol, Bronchospasm, Patient, Fine chemical, Pharmaceutical industry

The filing of applications for three new complex generics are additional proof points in our successful innovation journey.

Key Points: 
  • The filing of applications for three new complex generics are additional proof points in our successful innovation journey.
  • Today, about 90% of our generics R&D pipeline is made up of complex products.
  • Injectable propofol emulsion, the generic version of Diprivan®, is an IV general anesthetic and sedation drug.
  • Amneal plans to manufacture propofol emulsion internally by leveraging the Company’s global injectables infrastructure.

Visiox Pharma Licenses OMLONTI®

Retrieved on: 
星期三, 七月 19, 2023
Glaucoma, IOP, EP2, House of Santen, Ocular hypertension, Patient, NCE, Growth, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry, New chemical entity

Visiox plans to launch OMLONTI in early 2024, followed by once-daily PDP-716 (brimonidine) 0.35%, positioning the company to become a leader in glaucoma, a disease with significant impact on patients.

Key Points: 
  • Visiox plans to launch OMLONTI in early 2024, followed by once-daily PDP-716 (brimonidine) 0.35%, positioning the company to become a leader in glaucoma, a disease with significant impact on patients.
  • "We believe this is a compelling transaction, as it expands our addressable market opportunity enhancing our long-term growth and profitability."
  • The strategic license provides exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®.
  • Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of OMLONTI® in the U.S.

Nicox Provides Second Quarter 2023 Financial and Business Highlights

Retrieved on: 
星期三, 七月 19, 2023
Mont Blanc, NCX, Retina, Latanoprost, Priority review, IOP, COVID-19, Whistler, Nitric oxide, Ophthalmology, Intraocular pressure, Bausch & Lomb, Glaucoma, Ocular hypertension, Euronext Paris, Patient, Marshal of France, News, Cryptocurrency, Pharmaceutical industry

Cash position of €19.0 million, with a 12-month cash runway, as of June 30, 2023

Key Points: 
  • Cash position of €19.0 million, with a 12-month cash runway, as of June 30, 2023
    Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial and business highlights for the second quarter 2023 for Nicox SA and its subsidiaries (the “Nicox Group”).
  • We look forward to the expected launch of this in 2024, bringing an additional revenue stream to Nicox.
  • VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% U.S. prescriptions3 increased by 26.2% in the second quarter of 2023 compared to the same period in 2022.
  • Laboratorios Grin, Nicox’s exclusive partner for ZERVIATE™ (cetirizine ophthalmic solution), 0.24% in Mexico, has provided notice to Nicox of the termination of this agreement, effective July 23, 2023.

Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America

Retrieved on: 
星期二, 七月 18, 2023
General Health, Pharmaceutical, Optical, Health, Inflammation, Infection, Glaucoma, IOP, Keratitis, Medication, Harrow, Research, Vernal keratoconjunctivitis, Telecanthus, Ocular hypertension, Harrow Health, Patient, Allergic conjunctivitis, Conjunctivitis, Pharmaceutical industry, House of Santen

Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Key Points: 
  • Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
  • Under the terms of the agreement, Santen grants Visiox exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®.
  • Santen is eligible to receive sales milestone payments, as well as royalties on net U.S. sales of OMLONTI®.
  • Santen will receive an upfront payment for the asset transfer and the out-licensing and is eligible for royalties on net sales of Verkazia® and Cationorm® Plus.